Topotecan + Carboplatin + Veliparib
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-04-13 — Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia: Phase II randomized trial evaluating addition of PARP inhibitor veliparib to topotecan hydrochloride + carboplatin backbone vs. chemotherapy alone in advanced MPNs, AML, and CMML; rationale builds on DNA-damage repair biology in refractory myeloid disease (trial-early, no outcomes reported yet). (novelty: 3)
Open questions
Related
Contributing findings
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
13-apr-2026
novelty 3
per-area 3
introduces